+高级检索
首页 > 优先出版
PDF HTML阅读 XML下载 导出引用 引用提醒
外泌体的生物发生及其在神经退行性疾病中的作用
作者:
作者单位:

遵义医科大学贵州省普通高等学校传染病与生物安全特色重点实验室

基金项目:

国家自然科学基金委员会地区项目(82360859)；贵州省科技计划一般项目(黔科合基础-ZK[2021]一般547)


Biogenesis of exosomes and their role in neurodegenerative diseases
Author:
Affiliation:

1.Key Laboratory of Infectious Disease &2.Biosafety, and Provincial Department of Education, Zunyi Medical University

Fund Project:

1. Key Laboratory of Infectious Disease & Biosafety, and Provincial Department of Education, Zunyi Medical University, Zunyi 563006 China 2. School of Preclinical Medicine of Zunyi Medical University, Zunyi 563006, China

  • 摘要
    • | |
  • 访问统计
    • |
  • 参考文献 [59]
    • | | | |
  • 文章评论
    摘要:

    神经退行性疾病(neurodegenerative diseases, NDs)的发病率逐年增加,而目前针对NDs的药物基本是以症状为基础的,并不是治疗性的,不能阻止疾病进展。外泌体是细胞外囊泡的一个子集,人体内所有的细胞都可以产生外泌体,它被释放到细胞外环境后,通过多种方式发挥生物学效应。多种研究表明了外泌体虽然在中枢神经系统中具有两面性,但因其独特的生物学特性仍可作为NDs预防、缓解、治疗、诊断的工具。本文就外泌体的生物发生及其在神经退行性疾病中的作用作一综述,为临床治疗NDs提供新思路。

    Abstract:

    The incidence of neurodegenerative diseases (NDs) is increasing with the years, and current drugs targeting NDs are basically symptom-based, not therapeutic, so they can’t prevent disease progress. Exosomes are a subset of extracellular vesicles that can be produced by all cells in the human body and exert biological effects in a variety of ways after they are released into the extracellular environment. Many studies have shown that although exosomes have two sides in the central nervous system, they can still be used as a tool for the prevention, remission, treatment and diagnosis of NDs due to their unique biological characteristics. This article reviews the biogenesis of exosomes and their roles in neurodegenerative diseases, so as to provide new ideas for clinical treatment of NDs.

    参考文献
    [1] Yang Y, Zheng R, and Zhao L. Population Aging, Health Investment and Economic Growth: Based on a Cross-Country Panel Data Analysis [J]. Int J Environ Res Public Health, 2021, 18(4).
    [2] Golriz Khatami S, Mubeen S, and Hofmann-Apitius M. Data science in neurodegenerative disease: its capabilities, limitations, and perspectives [J]. Curr Opin Neurol, 2020, 33(2): 249-254.
    [3] Fan Y, Chen Z, and Zhang M. Role of exosomes in the pathogenesis, diagnosis, and treatment of central nervous system diseases [J]. J Transl Med, 2022, 20(1): 291.
    [4] Rastogi S, Sharma V, Bharti P S, et al. The Evolving Landscape of Exosomes in Neurodegenerative Diseases: Exosomes Characteristics and a Promising Role in Early Diagnosis [J]. Int J Mol Sci, 2021, 22(1).
    [5] Kalluri R and LeBleu V S. The biology, function, and biomedical applications of exosomes [J]. Science, 2020, 367(6478).
    [6] Kumari M and Anji A. Small but Mighty-Exosomes, Novel Intercellular Messengers in Neurodegeneration [J]. Biology (Basel), 2022, 11(3).
    [7] Doyle L M and Wang M Z. Overview of Extracellular Vesicles, Their Origin, Composition, Purpose, and Methods for Exosome Isolation and Analysis [J]. Cells, 2019, 8(7).
    [8] Verkhratsky A, Li Q, Melino S, et al. Can COVID-19 pandemic boost the epidemic of neurodegenerative diseases? [J]. Biol Direct, 2020, 15(1): 28.
    [9] Gurunathan S, Kang M H, and Kim J H. Diverse Effects of Exosomes on COVID-19: A Perspective of Progress From Transmission to Therapeutic Developments [J]. Front Immunol, 2021, 12: 716407.
    [10] Bazzan E, Tine M, Casara A, et al. Critical Review of the Evolution of Extracellular Vesicles'' Knowledge: From 1946 to Today [J]. Int J Mol Sci, 2021, 22(12).
    [11] Jan A T, Rahman S, Badierah R, et al. Expedition into Exosome Biology: A Perspective of Progress from Discovery to Therapeutic Development [J]. Cancers, 2021, 13(5).
    [12] Couch Y, Buzas E I, Di Vizio D, et al. A brief history of nearly EV-erything - The rise and rise of extracellular vesicles [J]. J Extracell Vesicles, 2021, 10(14): e12144.
    [13] Zhang Y, Bi J, Huang J, et al. Exosome: A Review of Its Classification, Isolation Techniques, Storage, Diagnostic and Targeted Therapy Applications [J]. Int J Nanomedicine, 2020, 15: 6917-6934.
    [14] Gurunathan S, Kang M H, and Kim J H. A Comprehensive Review on Factors Influences Biogenesis, Functions, Therapeutic and Clinical Implications of Exosomes [J]. Int J Nanomedicine, 2021, 16: 1281-1312.
    [15] Jan A T, Rahman S, Khan S, et al. Biology, Pathophysiological Role, and Clinical Implications of Exosomes: A Critical Appraisal [J]. Cells, 2019, 8(2).
    [16] Sonbhadra S, Mehak, and Pandey L M. Biogenesis, Isolation, and Detection of Exosomes and Their Potential in Therapeutics and Diagnostics [J]. Biosensors (Basel), 2023, 13(8).
    [17] Zhang Y, Liu Y, Liu H, et al. Exosomes: biogenesis, biologic function and clinical potential [J]. Cell Biosci, 2019, 9: 19.
    [18] Lau N C H and Yam J W P. From Exosome Biogenesis to Absorption: Key Takeaways for Cancer Research [J]. Cancers (Basel), 2023, 15(7).
    [19] Han Q F, Li W J, Hu K S, et al. Exosome biogenesis: machinery, regulation, and therapeutic implications in cancer [J]. Mol Cancer, 2022, 21(1): 207.
    [20] Mashouri L, Yousefi H, Aref A R, et al. Exosomes: composition, biogenesis, and mechanisms in cancer metastasis and drug resistance [J]. Mol Cancer, 2019,? 18(1): 75.
    [21] Choi H, Choi Y, Yim H Y, et al. Biodistribution of Exosomes and Engineering Strategies for Targeted Delivery of Therapeutic Exosomes [J]. Tissue Eng Regen Med, 2021, 18(4): 499-511.
    [22] Hu Q, Su H, Li J, et al. Clinical applications of exosome membrane proteins [J]. Precis Clin Med, 2020, 3(1): 54-66.
    [23] Gaurav I, Thakur A, Iyaswamy A, et al. Factors Affecting Extracellular Vesicles Based Drug Delivery Systems [J]. Molecules, 2021, 26(6).
    [24] Gurunathan S, Kang M H, Jeyaraj M, et al. Review of the Isolation, Characterization, Biological Function, and Multifarious Therapeutic Approaches of Exosomes [J]. Cells, 2019, 8(4).
    [25] Lai J J, Chau Z L, Chen S Y, et al. Exosome Processing and Characterization Approaches for Research and Technology Development [J]. Adv Sci (Weinh), 2022,? 9(15): e2103222.
    [26] Ramos J W, Jakubec M, Maple-Gr?dem J, et al. Plasma-derived exosome-like vesicles are enriched in lyso-phospholipids and pass the blood-brain barrier [J]. Plos One, 2020, 15(9).
    [27] Khatami S H, Karami N, Taheri-Anganeh M, et al. Exosomes: Promising Delivery Tools for Overcoming Blood-Brain Barrier and Glioblastoma Therapy [J]. Mol Neurobiol, 2023, 60(8): 4659-4678.
    [28] Ghosh S and Ghosh S. Exosome: The "Off-the-Shelf" Cellular Nanocomponent as a Potential Pathogenic Agent, a Disease Biomarker, and Neurotherapeutics [J]. Front Pharmacol, 2022, 13: 878058.
    [29] Lukiw W J and Pogue A I. Vesicular Transport of Encapsulated microRNA between Glial and Neuronal Cells [J]. Int J Mol Sci, 2020, 21(14).
    [30] Cieslik M, Nazimek K, and Bryniarski K. Extracellular Vesicles-Oral Therapeutics of the Future [J]. Int J Mol Sci, 2022, 23(14).
    [31] Passeri E, Elkhoury K, Morsink M, et al. Alzheimer''s Disease: Treatment Strategies and Their Limitations [J]. Int J Mol Sci, 2022, 23(22).
    [32] Staff N P, Jones D T, and Singer W. Mesenchymal Stromal Cell Therapies for Neurodegenerative Diseases [J]. Mayo Clin Proc, 2019, 94(5): 892-905.
    [33] Harrell C R, Volarevic A, Djonov V, et al. Mesenchymal Stem Cell-Derived Exosomes as New Remedy for the Treatment of Neurocognitive Disorders [J]. Int J Mol Sci, 2021, 22(3).
    [34] Breijyeh Z and Karaman R. Comprehensive Review on Alzheimer''s Disease: Causes and Treatment [J]. Molecules, 2020, 25(24).
    [35] Rastogi S, Sharma V, Bharti P S, et al. The Evolving Landscape of Exosomes in Neurodegenerative Diseases: Exosomes Characteristics and a Promising Role in Early Diagnosis [J]. International Journal of Molecular Sciences, 2021, 22(1).
    [36] He M, Zhang H-n, Tang Z-c, et al. Diagnostic and Therapeutic Potential of Exosomal MicroRNAs for Neurodegenerative Diseases [J]. Neural Plasticity, 2021,? 2021: 1-13.
    [37] Jia L, Zhu M, Kong C, et al. Blood neuro‐exosomal synaptic proteins predict Alzheimer''s disease at the asymptomatic stage [J]. Alzheimer''s Dementia, 2020,? 17(1): 49-60.
    [38] Jia L, Qiu Q, Zhang H, et al. Concordance between the assessment of Aβ42, T‐tau, and P‐T181‐tau in peripheral blood neuronal‐derived exosomes and cerebrospinal fluid [J]. Alzheimer''s Dementia, 2019, 15(8): 1071-1080.
    [39] Guo M, Hao Y, Feng Y, et al. Microglial Exosomes in Neurodegenerative Disease [J]. Front Mol Neurosci, 2021, 14: 630808.
    [40] Huang S, Liao X, Wu J, et al. The Microglial membrane receptor TREM2 mediates exosome secretion to promote phagocytosis of amyloid-beta by microglia [J]. FEBS Lett, 2022, 596(8): 1059-1071.
    [41] Zhang Y, Miao Y, Xiong X, et al. Microglial exosomes alleviate intermittent hypoxia-induced cognitive deficits by suppressing NLRP3 inflammasome [J]. Biol Direct, 2023, 18(1): 29.
    [42] Vaz M, Soares Martins T, and Henriques A G. Extracellular vesicles in the study of Alzheimer''s and Parkinson''s diseases: Methodologies applied from cells to biofluids [J]. J Neurochem, 2022, 163(4): 266-309.
    [43] Guo M, Yin Z, Chen F, et al. Mesenchymal stem cell-derived exosome: a promising alternative in the therapy of Alzheimer''s disease [J]. Alzheimers Res Ther, 2020, 12(1): 109.
    [44] Guy R and Offen D. Promising Opportunities for Treating Neurodegenerative Diseases with Mesenchymal Stem Cell-Derived Exosomes [J]. Biomolecules, 2020,? 10(9).
    [45] Doroszkiewicz J, Groblewska M, and Mroczko B. Molecular Biomarkers and Their Implications for the Early Diagnosis of Selected Neurodegenerative Diseases [J]. Int J Mol Sci, 2022, 23(9).
    [46] Gao C, Jiang J, Tan Y, et al. Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets [J]. Signal Transduct Target Ther, 2023, 8(1): 359.
    [47] Zhang F, Liu M, Tuo J, et al. Levodopa-induced dyskinesia: interplay between the N-methyl-D-aspartic acid receptor and neuroinflammation [J]. Front Immunol, 2023, 14: 1253273.
    [48] Heris R M, Shirvaliloo M, Abbaspour-Aghdam S, et al. The potential use of mesenchymal stem cells and their exosomes in Parkinson''s disease treatment [J]. Stem Cell Res Ther, 2022, 13(1): 371.
    [49] Huber C C and Wang H. Pathogenic and therapeutic role of exosomes in neurodegenerative disorders [J]. Neural Regen Res, 2024, 19(1): 75-79.
    [50] Natale F, Fusco S, and Grassi C. Dual role of brain-derived extracellular vesicles in dementia-related neurodegenerative disorders: cargo of disease spreading signals and diagnostic-therapeutic molecules [J]. Transl Neurodegener, 2022, 11(1): 50.
    [51] Xia X, Wang Y, and Zheng J C. Extracellular vesicles, from the pathogenesis to the therapy of neurodegenerative diseases [J]. Transl Neurodegener, 2022, 11(1): 53.
    [52] Zhu C, Bilousova T, Focht S, et al. Pharmacological inhibition of nSMase2 reduces brain exosome release and alpha-synuclein pathology in a Parkinson''s disease model [J]. Mol Brain, 2021, 14(1): 70.
    [53] Wang X, Zhou Y, Gao Q, et al. The Role of Exosomal microRNAs and Oxidative Stress in Neurodegenerative Diseases [J]. Oxid Med Cell Longev, 2020, 2020: 3232869.
    [54] Citterio L A, Mancuso R, Agostini S, et al. Serum and Exosomal miR-7-1-5p and miR-223-3p as Possible Biomarkers for Parkinson''s Disease [J]. Biomolecules, 2023, 13(5).
    [55] Ananbeh H, Vodicka P, and Kupcova Skalnikova H. Emerging Roles of Exosomes in Huntington''s Disease [J]. Int J Mol Sci, 2021, 22(8).
    [56] Yu Z, Teng Y, Yang J, et al. The role of exosomes in adult neurogenesis: implications for neurodegenerative diseases [J]. Neural Regen Res, 2024, 19(2): 282-288.
    [57] Mysiris D S, Vavougios G D, Karamichali E, et al. Post-COVID-19 Parkinsonism and Parkinson''s Disease Pathogenesis: The Exosomal Cargo Hypothesis [J]. Int J Mol Sci, 2022, 23(17).
    [58] Elizalde-Diaz J P, Miranda-Narvaez C L, Martinez-Lazcano J C, et al. The relationship between chronic immune response and neurodegenerative damage in long COVID-19 [J]. Front Immunol, 2022, 13: 1039427.
    [59] Jia Y, Yu L, Ma T, et al. Small extracellular vesicles isolation and separation: Current techniques, pending questions and clinical applications [J]. Theranostics, 2022, 12(15): 6548-6575.图1 外泌体的生成过程Figure 1.? The first invagination of the plasma membrane forms an early sorting endosome, then develops into a late sorting endosome, and completes the loading of DNA, non-coding RNA, proteins, etc., and then forms a multivesicular body, which is eventually either degraded or fused with the plasma membrane of the cell to release exosomes.
    相似文献
    引证文献
    网友评论
    网友评论
    分享到微博
    发 布
引用本文

复制
分享
文章指标
  • 点击次数:90
  • 下载次数: 0
  • HTML阅读次数: 0
  • 引用次数: 0
历史
  • 收稿日期:2024-04-15
  • 最后修改日期:2024-09-12
  • 录用日期:2024-10-29
您是第8868958 位访问者
版权所有:中国比较医学杂志 主管单位：中国科学技术协会 主办单位：中国实验动物学会 中国医学科学院医学实验动物研究所
地址：北京市朝阳区潘家园南里5号 邮 编 ：100021 电话：010-67779337 E-mail:bjb@cnilas.org
技术支持：北京勤云科技发展有限公司
防诈骗提示！请勿点击不明链接或添加个人微信。编辑部所有邮箱后缀均为@cnilas.org
关闭